The accuracy and effectiveness of routine population screening with mammography, prostate-specific antigen, and prenatal ultrasound: A review of published scientific evidence

International Journal of Technology Assessment in Health Care

Volumn 17, Issue 3, 2001, Pages 275-304

  Woolf, S H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Mammography; Prenatal ultrasound; Preventive medicine; Prostate specific antigen; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACCURACY; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CONGENITAL MALFORMATION; GESTATIONAL AGE; HUMAN; INTRAUTERINE GROWTH RETARDATION; MAMMOGRAPHY; MASS SCREENING; MEDICAL LITERATURE; PRENATAL CARE; PUBLICATION; REVIEW; SCREENING TEST; ULTRASOUND;

ADULT; BREAST NEOPLASMS; DIAGNOSTIC TESTS, ROUTINE; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; PREGNANCY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ULTRASONOGRAPHY, PRENATAL;

EID: 0034907660     PISSN: 02664623     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0266462301106021     Document Type: Review

References (269)

1. Deferred treatment of low grade stage T3 prostate cancer without distant metastases
2. Deferred treatment of clinically localized low grade prostate cancer: The experience from a prospective series at the Karolinska Hospital
3. Deferred treatment of locally advanced nonmetastatic prostate cancer: A long-term follow-up
4. Recent results of management of palpable clinically localized prostate cancer
5. Long-term survival among men with conservatively treated localized prostate cancer
6. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer
7. Fourteen years of follow-up from the Edinburgh randomized trial of breast-cancer screening
8. Reduced breast cancer mortality in women under age 50: Updated results from the Malmo Mammographic Screening Program
9. Using PSA to screen for prostate cancer: The Washington University experience
10. Early complications of contemporary anatomical radical retropubic prostatectomy
11. Adverse events after prostatectomy in Victorian public hospitals
12. Prostate cancer: Mortality and morbidity after non-curative treatment with aspects on diagnosis and treatment
13. Transrectal ultrasound examination of the prostate: Complications and acceptance by patients
14. Control of prostate cancer with radiotherapy: Long-term results
15. A high-sensitivity alternative to "routine" genetic amniocentesis: Multiple urinary analyses, nuchal thickness, and age
16. Randomization in the Canadian national breast screening study: A review for evidence of subversion
17. Randomized controlled trial of ultrasonographic screening in pregnancy
18. Breast cancer screening in 21 countries: Delivery of services, notification of results and outcomes ascertainment
19. The sensitivity of biological tissue to ultrasound
20. Prospective evaluation of prostate-specific antigen density and systematic biopsies for early detection of prostatic carcinoma
21. A critique of the decision analysis for clinically localized prostate cancer
22. Radiation risk of mammography related to benefit in screening programs: A favorable balance?
23. Identification of second-trimester fetuses with autosomal trisomy by use of a sonographic scoring index
24. Predictive value of ultrasound measurement in early pregnancy: A randomized controlled trial
25. Prostate-specific antigen density: A means of distinguishing benign prostatic hypertrophy and prostate cancer
26. Benefits and risks of screening mammography for women in their forties: A statistical appraisal
27. Outcome of fetuses with enlarged nuchal translucency and normal karyotype
28. The Gothenburg Breast Screening Trial: Preliminary results on breast cancer mortality for women aged 39-49
29. The natural history of prostate carcinoma based on a Danish population treated with no intent to cure
30. The review of randomization in the Canadian National Breast Screening Study: Is the debate over?
31. Mortality of patients with clinically localized prostate cancer treated with observation for 10 years or longer: A population-based registry study
32. Do women who undergo further investigation for breast screening suffer adverse psychological consequences? A multi-centre follow-up study comparing different breast screening result groups five months after their last breast screening appointment
33. Prostate-specific antigen and digital rectal examination in screening for prostate cancer: A community-based study
34. Ultrasonic recognition of the small-for-gestational age fetus
35. Does routine ultrasound screening improve outcome in pregnancy? Meta-analysis of various outcome measures
36. Effect of false-positive mammograms on interval breast cancer screening in a health maintenance organization
37. Routine ultrasound screening for the prediction of gestational age
38. Prostate cancer screening: A decision analysis
39. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer
40. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease
41. Conservative management of prostate cancer
42. Diagnosis, staging, and surgical treatment of prostatic carcinoma
43. Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies
44. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: An alternative model
45. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial
46. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results ofa multicenter clinical trial of 6,630 men
47. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediate-term results
48. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer
49. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening
50. Effect of breast cancer screening after age 65
51. Effectiveness of routine ultrasonography in detecting fetal structural abnormalities in a low-risk population
52. Comparing treatments for localized prostate cancer: Persisting uncertainty
53. Results of conservative management of clinically localized prostate cancer
54. Using an alternative data source to examine randomization in the Canadian National Breast Screening Study
55. Early detection of prostate cancer, II. Estimating the risks, benefits, and costs
56. Systematic reviews: Synthesis of best evidence for clinical decisions
57. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen
58. Sonographically measured nuchal skinfold thickness as a screening tool for Down syndrome: Results of a prospective clinical trial
59. A randomized trial of prenatal ultrasonographic screening: Impact on the detection, management and outcome of anomalous fetuses
60. Is an ultrasound assessment of gestational age at the first antenatal visit of value? A randomized clinical trial
61. Receiver-operator characteristic curves for the ultrasonographic prediction of small-for-gestational-age fetuses in low-risk pregnancies
62. Characteristics of men reporting for prostate cancer screening
63. Morbidity with contemporary prostate biopsy
64. First trimester screening for structural fetal abnormalities: Nuchal translucency sonography
65. A randomized controlled trial in a hospital population of ultrasound measurement screening for the small-for-date baby
66. Rates and correlates of discomfort associated with mammography
67. Ultrasound screening in pregnancy: A randomized controlled trial
68. Ten-year risk of false positive screening mammograms and clinical breast examinations
69. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with five years follow-up
70. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer
71. Incidence of and treatment for ductal carcinoma in situ of the breast
72. Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program
73. Serial prostate specific antigen screening for prostate cancer: A computer model evaluates competing strategies
74. Cancer surveillance series: Interpreting trends in prostate cancer, part 3: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality
75. Second trimester ultrasound screening performed by midwives: Sensitivity for detection of fetal anomalies
76. Characteristics of the possible effect on birth-weight following frequent prenatal ultrasound examinations
77. A randomized trial of routine prenatal ultrasound
78. Effect of prenatal ultrasound on perinatal outcome
79. National trends in the epidemiology of prostate cancer, 1973 to 1994: Evidence for the effectiveness of prostate-specific antigen screening
80. A review of twin pregnancy and perinatal mortality
81. Estimation of currently attainable benefit from mammographic screening of women aged 40-49 years
82. Strategies for improving sensitivity of screening mammography for women aged 40 to 49 years
83. Estimation of radiation risk from screening mammography: Recent trends and comparison with expected benefits
84. The four-chamber view and its sensitivity in detecting congenital heart defects
85. Cancer surveillance series: Interpreting trends in prostate cancer, part 2: Cause of death misclassification and the recent rise and fall in prostate cancer mortality
86. A decision analysis of alternative treatment strategies for clinically localized prostate cancer
87. Report of the International Workshop on Screening for Breast Cancer
88. A question that will not go away: At what age should mammographic screening begin?
89. Case-control study of screening for prostatic cancer by digital rectal examinations
90. The Stockholm Mammographic Screening Trial: Risks and benefits in age group 40-49 years
91. Risk-based recommendations for mammographic screening for women in their forties
92. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer
93. Routine obstetric ultrasound examinations in South Africa: Cost and effect on perinatal outcome - A prospective randomized controlled trial
94. Diagnosis of intrauterine growth retardation using ultrasound
95. Results of radical prostatectomy in men with clinically localized prostate cancer
96. Breast screening: The psychological sequelae of false-positive recall in women with and without a family history of breast cancer
97. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute
98. Is screening for breast cancer with mammography justifiable?
99. Quality of life following a false positive mammogram
100. Sonographic measurement of nuchal skin-fold thickness for detection of Down syndrome in the second-trimester fetus: A multicenter prospective study
101. Sensitivity of routine ultrasound screening of pregnancies in the Eurofetus database
102. Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer: A 15-year follow-up
103. Benefits of ultrasonic screening of a pregnant population
104. Systematic sextant biopsies in 651 patients referred for prostate evaluation
105. Cancer surveillance series: Interpreting trends in prostate cancer, part 1: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates
106. Early prostate cancer: The national results of radiation treatment from the Patterns of Care and Radiation Therapy Oncology Group studies with prospects for improvement with conformal radiation and adjuvant androgen deprivation
107. Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation
108. The necessity of a second prostate biopsy cannot be predicted by PSA or PSA derivatives (density or free: total ratio) in men with prior negative prostatic biopsies
109. Benefit of screening mammography in women aged 40-49: A new meta-analysis of randomized controlled trials
110. International trends and patterns of prostate cancer incidence and mortality
111. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening
112. Outcome analysis for women undergoing annual versus biennial screening mammography: A review of 24,211 examinations
113. Ultrasound scanning in women with raised alpha feto-protein: Long-term psychological effects
114. First trimester screening for fetal abnormalities
115. Comparison of prenatal ultrasound and postmortem findings in fetuses and infants with congenital heart defects
116. Comparison of prenatal ultrasound and post-mortem findings in fetuses and infants with central nervous system anomalies
117. Predictive properties of serum prostate-specific antigen testing in a community-based setting
118. Screening digital rectal examination and prostate cancer mortality: A population-based case-control study
119. Routine screening for intrauterine growth retardation in Germany: Low sensitivity and questionable benefit for diagnosed cases
120. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results
121. Expectant management of early stage prostatic cancer: Swedish experience
122. Fifteen-year survival in prostate cancer: A prospective, population-based study in Sweden
123. Quality of life in T1-3N0 prostate cancer patients treated with radiation therapy with minimum 10-year follow-up
124. MULTISCAN - A Scandinavian multicenter second trimester obstetric ultrasound and serum screening study
125. Serum prostate-specific antigen levels (PSA) in men without clinical evidence of prostate cancer: Age-specific reference ranges for total PSA, free PSA, and percent free PSA
126. Positive predictive value of screening mammography by age and family history
127. Variability and accuracy in mammographic interpretation using the American College of Radiology Breast Imaging Reporting and Data System
128. Effect of age, breast density, and family history on the sensitivity of first screening mammography
129. Efficacy of screening mammography: A meta-analysis
130. Continuing screening mammography in women aged 70 to 79 years: Impact on life expectancy and cost effectiveness
131. Routine ultrasound screening in pregnancy and the children's subsequent neurologic development
132. Routine ultrasound screening in pregnancy and the children's subsequent growth, vision and hearing
133. Sonographic screening to detect fetal cardiac anomalies: A 5-year experience with 111 abnormal cases
134. Physiologic (intraindividual) variation of serum prostate-specific antigen in 814 men from a screening population
135. The Canadian National Breast Screening Study: A critical review
136. Statistical power in breast cancer screening trials and mortality reduction among women 40-49 years of age with particular emphasis on the National Breast Screening Study of Canada
137. Screening for prostate cancer: A decision analytic view
138. Prostate cancer screening: What we know and what we need to know
139. Survival after radical prostatectomy
140. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen
141. Screening decreases prostate cancer death: First analysis of the 1988 Quebec prospective randomized controlled trial
142. The "vanishing twin": Ultrasonographic assessment of fetal disappearance in the first trimester
143. Detection of small-for-gestational-age fetuses by ultrasound screening in a high-risk population: A randomized controlled study
144. Variations in individual radiation dose in a breast screening program and consequences for the balance between risk and benefit
145. A randomized trial of prenatal ultrasonographic screening: Impact on maternal management and outcome
146. Three-dimensional conformal radiation therapy in localized carcinoma of the prostate: Interim report of a phase 1 dose-escalation study
147. Psychosocial impact of cancer screening
148. Psychological and behavioral implications of abnormal mammograms
149. Extended experience with radical prostatectomy for clinical stage T3 prostate cancer
150. Sensitivity and specificity of routine antenatal screening for congenital anomalies by ultrasound: The Belgian Multicentric Study
151. End-result of routine ultrasound screening for congenital anomalies: The Belgian Multicentric Study 1984-1992
152. Neglected aspects of false-positive findings in mammographic screening
153. Mammography outcomes in a new practice setting by age: Prognostic factors, sensitivity, and positive biopsy rate
154. Quality-of-life outcomes in men treated for localized prostate cancer
155. A cost-effectiveness analysis of screening for carcinoma of the prostate by digital examination
156. Psychologic distress in women with abnormal findings in mass mammography screening
157. Changes in prostate cancer incidence and treatment in USA
158. An assessment of radical prostatectomy: Time trends, geographic variation, and outcomes
159. Breast cancer screening for elderly women with and without comorbid conditions: A decision analysis model
160. Mortality of patients after radical prostatectomy: Analysis of recent Medicare claims
161. Radiation risk and mammographic screening of women from 40 to 49 years of age: Effect on breast cancer rates and years of life
162. Watchful waiting or watchful progression: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma
163. Characteristics of prostate cancer detected in the American Cancer Society National Prostate Cancer Detection Project
164. The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the U.S.
165. Downward trend in prostate cancer mortality in Quebec and Canada
166. Psychological reactions to ultrasound: Examination during pregnancy
167. Screening for prostate cancer
168. Canadian National Breast Screening Study, part 1: Breast cancer detection and death rates among women aged 40 to 49 years
169. Canadian National Breast Screening Study, part 1: Breast cancer detection and death rates among women aged 50 to 59 years
170. The Canadian National Breast Screening Study: Update on breast cancer mortality
171. The evaluation and treatment of men with asymptotic prostate nodules in primary care: A decision analysis
172. Age-specific references ranges for serum prostate-specific antigen in black men
173. Treatment selection in ductal carcinoma in situ
174. Breast cancer: Age-specific growth rates and screening strategies
175. A trial to study the effect on breast cancer mortality of annual mammographic screening in women starting at age 40
176. National patterns of prostate cancer treatment by radical prostatectomy: Results of a survey by the American College of Surgeons Commission on Cancer
177. Estimating the accuracy of screening mammography: A meta-analysis
178. Ultrasound for fetal assessment in early pregnancy
179. Screening for small-for-dates fetuses: A controlled trial
180. Screening for the small-for-dates fetus: A two-stage ultrasonic examination schedule
181. Effects of frequent ultrasound during pregnancy: A randomized controlled trial
182. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort
183. Doppler ultrasonography in suspected intrauterine growth retardation: A randomized controlled trial
184. Humerus and femur length shortening in the detection of Down's syndrome
185. Breast cancer screening with mammography: Overview of Swedish randomized trials
186. Dose dependent effect of ultrasound on fetal weight in mice
187. Prostate-specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
188. Serum prostate-specific antigen in a community-based population of healthy men: Establishment of age-specific reference ranges
189. Women with false positive screening mammograms: How do they cope?
190. Morbidity and mortality following radical prostatectomy: A national analysis of Civilian Health and Medical Program of the Uniformed Services beneficiaries
191. False positive rate of screening mammography
192. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy
193. Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer
194. Long-term experience of general ultrasound screening in pregnancy
195. Screening mammography behavior after a false positive mammogram
196. The role of increasing detection in the rising incidence of prostate cancer
197. Third trimester placental grading by ultrasonography as a test of fetal wellbeing
198. Screening digital rectal examination and prostate cancer mortality: A case-control study
199. The changing pattern of prostate cancer at the time of diagnosis: Characteristics of screen detected prostate cancer in a population based screening study
200. Diagnostic effectiveness of ultrasound in detection of neural tube defect: The South Wales experience of 2509 scans (1977-1982) in high-risk mothers
201. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota
202. Diagnostic ultrasound: Early detection of fetal neural tube defects
203. Can decision analysis help us decide whether ultrasound screening for fetal anomalies is worth it?
204. Screening for prostate cancer
205. Ultrasound screening and perinatal mortality: Controlled trial of systematic one-stage screening in pregnancy. The Helsinki Ultrasound Trial
206. Fetal anomalies in a controlled one-stage ultrasound screening trial. A report from the Helsinki Ultrasound Trial
207. Predictive value, sensitivity, and specificity of ultrasonic targeted imaging for fetal anomalies in gravid women at high risk for birth defects
208. Routine ultrasonography in utero and school performance at age 8-9 years
209. Ultrasound during pregnancy and subsequent childhood non-right handedness: A meta-analysis
210. Comparison of long-term psychological responses of women after pregnancy termination due to fetal anomalies and after perinatal loss
211. Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age
212. Cause of death in men diagnosed with prostate carcinoma
213. Tumor volume and stage in carcinoma of the prostate detected by elevations in prostate specific antigen
214. Early detection of prostate cancer
215. Conservative management of prostate cancer
216. The European Randomized Study of Screening for Prostate Cancer (ERSPC): An update
217. Screening mammography re-evaluated
218. A randomized study of fetal abdominal diameter and fetal weight estimation for detection of light-for-gestation infants in low-risk pregnancies
219. Serum prostate-specific antigen discriminates weakly between men with benign prostatic hyperplasia and patients with organ-confined prostate cancer
220. Ten- to fourteen-year effect of screening on breast cancer mortality
221. Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis
222. Routine radiographer screening for fetal abnormalities by ultrasound in an unselected low risk population
223. Quality of life and treatment outcomes: Prostate carcinoma patients' perspectives after prostatectomy or radiation therapy
224. Prostate cancer in Saskatchewan Canada, before and during the PSA era
225. Benefit of mammography screening in women ages 40 to 49 years. Current evidence from randomized controlled trials
226. The nature of prostate cancer detected through prostate specific antigen based screening
227. Longitudinal screening for prostate cancer with prostate-specific antigen
228. Trends in the curative treatment of localized prostate cancer after the introduction of prostate-specific antigen: Data from the Rotterdam Cancer Registry
229. Biological determinants of cancer progression in men with prostate cancer
230. Physiological variation of serum prostate specific antigen (PSA) from a screening population in the range of 4-10 ng/mL using the Hybritech Tandem-R PSA assay
231. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: The Prostate Cancer Outcome Study
232. o or T1c prostate cancer: Nonpalpable disease identified by elevated serum prostate-specific antigen concentration
233. Breast cancer screening with mammography in women aged 40-49 years
234. Efficacy of breast cancer screening by age: New results from the Swedish Two-County Trial
235. Update of the Swedish Two-County Trial of breast cancer screening: Histologic grade-specific and age-specific results
236. Patient-reported impotence and incontinence after nerve-sparing radical prostatectomy
237. Evaluation of the bioeffects of prenatal ultrasound exposure in the Cynomolgus Macaque (Macaca fascicularis), part 1: Neonatal/infant observations
238. Evaluation of the bioeffects of prenatal ultrasound exposure in the Cynomolgus Macaque (Macaca fascicularis), part 3: Developmental and hematologic studies
239. The excess of patients with advanced breast cancer in young women screened with mammography in the Canadian National Breast Screening Study
240. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates
241. Role of radical prostectomy in patients with prostate cancer of high Gleason score
242. Quality of controlled clinical trials. The case of imaging ultrasound in obstetrics: A review
243. Impact of routine screening for adenocarcinoma of the prostate on stage distribution
244. The value of prostate specific antigen in early diagnosis of prostate cancer: The study of men born in 1913
245. Diagnostic value of percent free prostate-specific antigen: Retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL
246. Ultrasound scanning in pregnancy: Consumer reactions
247. A comparison between ultrasound and a reliable last menstrual period as predictors of the day of delivery in 15,000 examinations
248. Fetal outcome in pregnancies defined as post-term according to the last menstrual period estimate, but not according to the ultrasound estimate
249. Should maternal alpha-fetoprotein estimation be carried out in centers where ultrasound screening is routine? A sensitivity analysis approach
250. In-situ breast cancer: The EORTC consensus meeting
251. Psychological aspects of ultrasound imaging during pregnancy
252. Adding free to total prostate-specific antigen levels in trials of prostate cancer screening
253. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters
254. Effects of routine one-stage ultrasound screening in pregnancy: A randomized controlled trial
255. A decision analysis of alternative treatment for clinically localized prostate cancer
256. The Swedish prostate cancer paradox
257. Expectant management of clinically localized prostatic cancer
258. Routine ultrasound screening for antenatal detection of intrauterine growth retardation
259. The present place of routine ultrasound screening
260. A structured literature review of treatment for localized prostate cancer
261. Digital rectal examination and mortality from prostate cancer
262. Diagnostic testing following screening mammography in the elderly
263. The Prostate Cancer Intervention Versus Observational Trial: A randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer
264. An evaluation of radical prostatectomy at Veterans Affairs Medical Centers: Time trends and geographic variation in utilization and outcomes
265. Screening for prostate cancer with prostate-specific antigen: An examination of the evidence
266. Assay for prostate specific antigen (PSA): Problems and possible solutions
267. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer
268. The effect of the amount of feedback on anxiety levels during ultrasound scanning